Nikhil Jaganathan

Mr. Nikhil Jaganathan

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
NJNikhil Jaganathan
Nikhil Jaganathan
YKYounghoon Kwon
Younghoon Kwon
WHWilliam Healy
William Healy
VTVarsha Taskar
Varsha Taskar
Obstructive sleep apnea (OSA) is a prevalent pathology with current modalities of treatment including continuous positive airway pressure (CPAP), surgery, weight loss, hypoglossal nerve stimulation, and pharmacotherapy. While CPAP is the current standard treatment for OSA, lack of tolerance and side effects necessitate alternative modalities of treatment. Various pharmacologic agents exist with mechanisms that may target OSA. Early trials have demonstrated efficacy of noradrenergic-antimuscarinic combinations to stimulate the airway, promote pharyngeal muscle tone, and prevent airway collapse. These agents, which we discuss in detail, have demonstrated significant reductions in apnea-hypopnea index (AHI) and lowest oxygen saturations based on preliminary studies. Glucagon-like peptide 1 receptor agonists (GLP-1RA), which stimulate endogenous insulin, reducing glucagon release, and decreasing gastric emptying, have shown positive results for OSA patients through weight loss with reductions in AHI. In this narrative review article, we highlight the mechanisms, current data, and future potential for multiple drug classes, including respiratory stimulants and GLP-1RAs.

12 November 2025 in Cancers
Verified
Journal Article
Open access
PDF file
EWElena Wernecke
Elena Wernecke
FRFaten Ragaban
Faten Ragaban
PRPeter B. Rosenquist
Peter B. Rosenquist
NJNikhil Jaganathan
Nikhil Jaganathan
WHWilliam Healy
William Healy
EFEgidio Giacomo Del Fabbro
Egidio Giacomo Del Fabbro
Chemotherapy-induced peripheral neuropathy (CIPN) impairs quality of life and may result in discontinuation of anti-neoplastic therapy. In older patients, CIPN is associated with reduced executive function, more severe pain, comorbidities and polypharmacy. The use of magnetic fields to modulate central and peripheral neurons may offer some benefit for relieving neuropathic pain, with few adverse effects. The evidence of the benefits of using transcranial magnetic stimulation (TMS) or peripheral magnetic stimulation (PMS) in patients with CIPN is evaluated in this narrative review. Improved patient-reported outcomes and more rapid nerve conduction velocities in preliminary trials suggest efficacy in patients with CIPN. The potential for additional, broader applications in CIPN includes biomarkers of progression to chronic neuropathic pain, opioid-sparing benefits, and mitigating associated depression and anxiety. Because magnetic stimulation (MS) is relatively resource intense and time consuming, requiring multiple sessions of therapy, its availability is still limited, and multi-center trials are challenging. Further research with sham-controlled clinical trials, using standardized MS techniques and outcome assessments are needed.

4 November 2025 in BMJ Supportive & Palliative Care
Verified
Journal Article
Closed access
PDF file
NJNikhil Jaganathan
Nikhil Jaganathan
NRNithya Rajanala
Nithya Rajanala
FRFaten Ragaban
Faten Ragaban
EFEgidio Del Fabbro
Egidio Del Fabbro
WHWilliam J Healy
William J Healy
PRPeter B Rosenquist
Peter B Rosenquist
Background: Transcranial magnetic stimulation (TMS) is a non-invasive neurostimulation technique currently approved by the Food and Drug Administration for the treatment of depression, migraines with aura and obsessive-compulsive disorder. While there is ample evidence supporting the safety and efficacy of TMS in treating these conditions, there is limited exploration of the application of TMS in the context of palliative care. Methods: In the wake of a preliminary study of ‘accelerated’ repetitive TMS promising symptomatic improvement in depression and anxiety in palliative care patients, we evaluated the use of TMS in addressing a broad spectrum of palliative care-focused symptoms based on the Edmonton Symptom Assessment System (ESAS) in numerous studies. Results: Positive effects were observed in modulating depression, anxiety, sleep, dyspnoea, appetite, peripheral neuropathy, non-neuropathic pain, fatigue and feelings of well-being. Although cachexia and nausea are symptoms classified under the ESAS, our literature search yielded no search results regarding TMS treatment. Conclusion: Larger-scale clinical studies with diverse samples are warranted, and future exploration is necessary to discover additional methodologies for TMS therapy. In this narrative review article, we discuss the current studies to analyse the supporting data, efficacy, safety, mechanisms and the therapeutic potential of TMS use across various conditions within palliative care.

21 August 2026 in Advances in Geriatric Medicine and Research
Verified
Journal Article
Open access
PDF file
NJNikhil Jaganathan
Nikhil Jaganathan
VGVarun Goel
Varun Goel
XLXiaoyue Liu
Xiaoyue Liu
WenZhan SongWenZhan Song
WenZhan Song
YKYounghoon Kwon
Younghoon Kwon
WHWilliam Healy
William Healy
With an aging population and greater prevalence of metabolic disorders, obstructive sleep apnea (OSA) is increasingly observed in older patients. OSA in older adults often occurs in the setting of various comorbidities, such as cognitive, cardiac, and metabolic dysfunction, placing these patients at greater risk. Continuous positive airway pressure (CPAP) is the first-line treatment for OSA in most patients, but adherence with CPAP decreases with increasing age. Current literature on considerations and efficacy of treatment modalities for OSA in older patients is limited. This narrative review summarizes current evidence on CPAP and non-CPAP therapies of OSA in older adults with particular attention to age-specific differences in clinical presentation, diagnostic challenges, and implications for quality of life. Relevant guidelines, clinical studies, and systematic reviews selected from the PubMed and Cochrane databases through April 2026 were summarized and categorized based on type of therapy. Some non-CPAP alternatives appear promising or effective in selected adults for improving metrics of sleep, quality of life, and mitigating comorbidities, but for geriatric-specific comparative evidence remains limited, indirect, observational, or derived from adults substantially younger than the target population. Lifestyle modifications, positional therapy, and oral appliances may yield benefits in older patients comparable to those seen in their younger counterparts, but age-stratified studies are limited. While pharmacotherapy is an area of emerging study, GLP-1 RAs show significant early potential with multifaceted benefits, although supporting studies have been primarily conducted in middle-aged adults. Hypoglossal nerve stimulation has emerged as a prominent OSA treatment alternative with improved adherence compared to CPAP in in small elderly-specific studies. OSA management in older patients is highly nuanced with multifactorial consideration of polypharmacy, comorbidities, and patient preferences to optimize patient outcomes. Larger-scale, prospective studies specific to older patients are warranted to assess treatment efficacy, adherence, and adverse effects in this population.

20 April 2024 in Cureus
Verified
Journal Article
Open access
PDF file
NJNikhil Jaganathan
Nikhil Jaganathan
MDMallikarjuna Devarapalli
Mallikarjuna Devarapalli
VKVikas Kumar
Vikas Kumar
Impella 5.5 (Abiomed Inc., Danvers, MA, USA) is a surgically implanted mechanical circulatory support device that helps support hemodynamically compromised patients. The device's risks and benefits must be entirely known, especially in the electrophysiology lab. Due to unexpected hemodynamic changes during pace mapping and ablation, such as ventricular tachycardia (VT) and asystole, it is sometimes necessary to implement chemical support with inotropic agents such as epinephrine or mechanical support with devices such as an Impella. We present the case of a 72-year-old male with a biventricular implantable cardioverter-defibrillator (ICD) (Medtronic, Minneapolis, MN, USA) placed for refractory VT presenting for VT ablation. He had ischemic cardiomyopathy with a left ventricular ejection fraction (LVEF) of 33% and medical history of cardiac sarcoidosis, hypertension, hyperlipidemia, pulmonary embolism, left bundle branch block, and coronary artery disease. Due to the nature of the procedure and his history of arrhythmia, the patient was deemed a candidate for Impella 5.5. After evaluating patient risk factors, the cardiothoracic anesthesia team developed a strategic approach with imaging (including radiographic and echocardiographic imaging), Impella monitoring, and pharmacologic management with inotropes and vasopressors, allowing for uncomplicated perioperative management during the ablation. Given the procedure's intricacies and the patient's arrhythmia history, the medical team identified the patient as suitable for Impella 5.5 due to better performance and greater cardiac output than Impella 2.5 (Abiomed Inc., Danvers, MA, USA). Following a thorough assessment of the patient's risk factors, the cardiothoracic anesthesia team devised a comprehensive strategy to facilitate smooth perioperative management during the ablation, minimizing complications. The VT ablation procedure was performed successfully and effectively terminated the arrhythmia. However, the patient developed multifaceted postoperative complications, including cardiogenic shock, hemorrhagic shock, dyspnea, anemia, gastrointestinal abnormalities, and sepsis. This case represents a highly complex patient scenario under the care of the cardiovascular anesthesiologist due to the nature of the procedure and numerous cardiovascular comorbidities, low ejection fraction, ICD placement, and malignant ventricular arrhythmia. We discuss the various perioperative management strategies and how they are tailored to such patients, including pharmacologic intervention, anesthesia administration, imaging modalities, and postoperative care. The purpose of this case report is to delineate the role of Impella 5.5 in perioperative care for high-risk VT ablation patients. We discuss the progression, pathophysiology, and management of this patient's multisystem complications following the procedure. We also highlight the use of Impella 5.5 in the electrophysiology lab and the anesthesia considerations, safeguards, and management strategies to optimize perioperative outcomes and avoid complications.

1 June 2025 in Southern Medical Journal
Verified
Journal Article
Closed access
ADAdrian Davies
Adrian Davies
NJNikhil Jaganathan
Nikhil Jaganathan
YCYeilim Cho
Yeilim Cho
XLXiaoyue Liu
Xiaoyue Liu
SHSara J. Healy
Sara J. Healy
WHWilliam Healy
William Healy
Obstructive sleep apnea (OSA), a condition with high prevalence, is characterized by reduced dilatory function of pharyngeal muscles, which can be influenced by upper airway narrowing, dilator muscle dysfunction, respiratory dysfunction, and genetics. Three of the most clinically important phenotypes of OSA include disturbed sleep, excessive sleepiness, and minimal symptoms, with varying implications for management and morbidity. This article reviews current perspectives on these OSA phenotypes, as well as the process of confirming a diagnosis of OSA. Lastly, this article delineates various current and future OSA therapy approaches through review and analysis of the existing literature with discussion on the outlook for OSA treatment.